<SEC-DOCUMENT>0001019687-15-003425.txt : 20150911
<SEC-HEADER>0001019687-15-003425.hdr.sgml : 20150911
<ACCEPTANCE-DATETIME>20150910173435
ACCESSION NUMBER:		0001019687-15-003425
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150910
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150911
DATE AS OF CHANGE:		20150910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SIMULATIONS PLUS INC
		CENTRAL INDEX KEY:			0001023459
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
		IRS NUMBER:				954595609
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32046
		FILM NUMBER:		151101904

	BUSINESS ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		STREET 2:		*
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
		BUSINESS PHONE:		661-723-7723

	MAIL ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>simulations_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED
STATES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">September 10, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">(Date
of the earliest event reported)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Simulations Plus, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">California</FONT></TD>
    <TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">001-32046</FONT></TD>
    <TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">95-4595609</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(Commission File Number)</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">42505 10<SUP>th</SUP> Street West,
Lancaster, California 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">(Address
of principal executive offices) (Zip Code)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">661-723-7723</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">Registrant's
telephone number, including area code</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b)) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[_] Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>Item 8.01<FONT STYLE="font-size: 10pt">&#9;Other
Events</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2015, Simulations Plus,
Inc., a California corporation (the &quot;Company&quot;), issued a press release announcing preliminary revenues for the fourth
fiscal quarter of fiscal year 2015 ended August 31, 2015. The press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained in this Current
Report on Form 8-K shall not be deemed to be &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the &quot;Exchange Act&quot;), or otherwise subject to the liabilities of that section, nor shall such information
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;),
or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in
this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Current
Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K may contain
forward-looking statements that are made pursuant to the safe harbor provisions of Section 21E of the Exchange Act. The forward-looking
statements in this Current Report on Form 8-K are not historical facts, do not constitute guarantees of future performance and
are based on numerous assumptions which, while believed to be reasonable, may not prove to be accurate. Any forward-looking statements
in this Current Report on Form 8-K do not constitute guarantees of future performance and involve a number of factors that could
cause actual results to differ materially, including risks more fully described in our most recently filed Quarterly Report on
Form 10-Q and Annual Report on Form 10-K. The Company assumes no obligation to update any forward-looking information contained
in this Current Report or with respect to the announcements described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&#9;Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#9;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in">99.1</TD><TD>Press release issued on September 10, 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">SIMULATIONS PLUS, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">Dated: September 10, 2015</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ John R. Kneisel</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">John R. Kneisel<BR>Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>simulations_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_002.jpg" ALT="" STYLE="width: 216px; height: 80px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Further Information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">42505 10<SUP>th</SUP> Street West</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lancaster, CA 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 34%"><font style="font-size: 10pt"><b>CONTACT</b>:</font></td>
    <TD STYLE="width: 15%">&nbsp;</td>
    <TD STYLE="width: 51%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-decoration: underline"><font style="font-size: 10pt"><u>Simulations Plus Investor Relations</u></font></td>
    <TD>&nbsp;</td>
    <TD STYLE="text-decoration: underline"><font style="font-size: 10pt"><u>Hayden IR</u></font></td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">Ms. Renee Bouche</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">Mr. Cameron Donahue</font></td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">661-723-7723</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">651-653-1854</font></td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">renee@simulations-plus.com</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">cameron@haydenir.com</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Immediate Release:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 10, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Simulations
Plus Reports Preliminary Revenues for </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Fourth
Quarter and Fiscal Year 2015</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Company Reports Record Fourth-Quarter
and Full-Year Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LANCASTER, CA, September 10, 2015 &ndash;
</B>Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and
development, today released preliminary revenues for its fiscal fourth quarter (4QFY15) and full-year 2015 (FY2015) ended August
31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. John R Kneisel, chief financial officer
of Simulations Plus, stated: &ldquo;We have just completed our first year of operations following our September 2014 acquisition
of Cognigen Corporation, an acquisition which delivered the expected benefits such as expanded addressable market, increased scale,
and greater profitability. In accordance with our policy to release timely financial information to our shareholders, we are releasing
preliminary consolidated revenues for 4QFY15. Net income will not be known until income taxes have been determined and our auditors
review our Annual Report on Form 10-K. We expect to file our 10-K with the U.S. Securities and Exchange Commission on or before
the November 30, 2015 deadline.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preliminary results for the quarter:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Preliminary revenues for 4QFY15 increased 82.9% to $3.65 million, compared to $2.0 million reported
for Simulations Plus for 4QFY14.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Consolidated software and software-related services increased 14.9% to a record $2.18 million for
4QFY15 compared to 4QFY14.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD>Cognigen Corporation 4QFY15 revenues were $1.34 million compared to $1.40 million in the third quarter of this fiscal year.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">For the quarter, approximately 59.7% of revenues came from software and software-related services,
and approximately 40.3% of revenues came from consulting studies and collaborations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preliminary results for the fiscal year:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Preliminary revenues for FY2015 were $18.26 million, compared to $11.46 million for FY2014; this
represents an increase of 59.3%, or $6.80 million. $5.15 million of the 2015 revenue increase is attributed to the Cognigen Corporation
acquisition.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">For FY2015, approximately 68.5% of revenues came from software licenses and software-related services,
and approximately 31.5% of revenues came from consulting studies and collaborations.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Cash as of September 8, 2015, was $8.4 million, after a dividend distribution of approximately
$847,000 was made on July 30, 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">John DiBella, vice president for marketing
and sales of Simulations Plus, said: &ldquo;We continue to ride a wave of positive sales momentum on all fronts, as we saw strong
gains in revenue from both software licenses and consulting services. It is important to note when comparing 4<SUP>th</SUP> quarters,
in 4QFY14 we instituted changes to how multiyear license revenue was recognized and, as a result, accrued a positive adjustment
to revenue from previous quarters of $0.19 million. Eliminating this one-time correction, revenue for software and software-related
services would have increased 26.7%. The recent news regarding the second U.S. FDA grant award in as many years further confirms
our position as the premier provider of modeling and simulation software and services for the pharmaceutical industry. This, coupled
with several new product releases expected this fall, positions us nicely as we enter FY16.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ted Grasela, president of Simulations Plus,
added: &ldquo;I&rsquo;m encouraged by the strong preliminary results we are reporting today. We continue to identify ways in which
we can improve the profitability of the company and work together on solving some of the vexing industry challenges of pharmaceutical
research and development. I&rsquo;m looking forward to fiscal year 2016 and working with the Simulations Plus and Cognigen teams
to continue the excellent history of growth for Simulations Plus.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Simulations Plus, Inc., is a premier developer
of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research
by major pharmaceutical and biotechnology companies worldwide. For more information, visit our Web site at www.simulations-plus.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cognigen Corporation, a wholly owned subsidiary
of Simulations Plus, Inc., is a leading provider of population modeling and simulation contract research services for the pharmaceutical
and biotechnology industries. For more information, visit Cognigen&rsquo;s website at www.cognigencorp.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The combined company is a global leader
focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology
agents. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical
science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic
modeling and simulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Follow Us on Twitter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Safe Harbor Statement Under the Private
Securities Litigation Reform Act of 1995</B> &ndash; With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could
differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited
to: our ability to maintain our competitive advantages, acceptance of new software products and improved versions of our existing
software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to
continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors
is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !J 4T# 2(  A$! Q$!_\0
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4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
